Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?

Rheumatology (United Kingdom)

Volumn 54, Issue 7, 2015, Pages 1257-1261

  de Groot, Lodewijk ^a   Jager, Nynke A ^a   Westra, Johanna ^a   Smit, Andries J ^a   Kallenberg, Cees G M ^a   Posthumus, Marcel D ^b   Bijl, Marc ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

Author keywords

Advanced glycation end products; Atherosclerosis; Endothelial cell activation; Endothelial dysfunction; Intima media thickness; Rheumatoid arthritis; Small artery elasticity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; SOLUBLE VASCULAR CELLULAR ACTIVATION MOLECULE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; AUTOFLUORESCENCE; BLOOD VESSEL PARAMETERS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DAS28; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; ELASTICITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SMALL ARTERY ELASTICITY; SYSTOLIC BLOOD PRESSURE;

EID: 84936852624     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu459     Document Type: Article

References (20)

1. van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009;68:1395-400.
2. de Groot L, Posthumus MD, Kallenberg CG, Bijl M. Risk factors and early detection of atherosclerosis in rheumatoid arthritis. Eur J Clin Invest 2010;40:835-42.
3. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121(Suppl 1):S21-31.
4. de Groot L, Hinkema H, Westra J et al. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Res Ther 2011; 13:R205.
5. Lander HM, Tauras JM, Ogiste JS et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272:17810-4.
6. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
7. Vermeer M, Kuper HH, Hoekstra M et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011;63:2865-72.
8. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
9. Crilly MA, Kumar V, Clark HJ et al. Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose-response relationship independent of established cardiovascular risk factors. Rheumatology 2009;48: 1606-12.
10. Nienhuis HL, de Leeuw K, Bijzet J et al. Small artery elasticity is decreased in patients with systemic lupus erythematosus without increased intima media thickness. Arthritis Res Ther 2010;12:R181.
11. Sramek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 2000;35:699-706.
12. Meerwaldt R, Graaff R, Oomen PH et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47: 1324-30.
13. Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003;48:72-80.
14. Sokolove J, Bromberg R, Deane KD et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012;7: e35296.
15. Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 2012;41:669-75.
16. Gerrits EG, Lutgers HL, Kleefstra N et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31:517-21.
17. Kirkham BW, Wasko MC, Hsia EC et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 2014;73:161-9.
18. Wong M, Oakley SP, Young L et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1277-84.
19. Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106: 2184-7.
20. Guin A, Chatterjee Adhikari M, Chakraborty S, Sinhamahapatra P, Ghosh A. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum 2013;43:48-54.